Current State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
|
|
- Anne Greene
- 6 years ago
- Views:
Transcription
1 Activity Code FA376
2 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago
3 Learning Objectives Upon completion of this presentation, learners should be better able to: 1. Discuss the safety and efficacy of current treatment options for HIV and HCV 2. Discuss the safety and efficacy of near term agents for those co-infected 3. Review the pipeline of HCV agents in phase 2/3 trials for HCV mono-infection
4 Disclosures Grant Support: Vertex, Genentech, Janssen, Gilead, AbbVie, BMS, Boehringer- Ingelheim Medical Advisory: AbbVie, Gilead, Janssen, Idenix, Salix
5 Cumulative mortality (%) HCV Viral Replication Increases All Cause Mortality All Causes Anti-HCV seropositives, HCV RNA detectable Anti-HCV seropositives, HCV RNA undetectable Anti-HCV seronegatives 30.1% 25 P<0.001 for comparison among three groups P<0.001 for HCV RNA detectable vs. undetectable % 12.4% Follow-up years Lee MH, et al. J Infect Dis. 2012;206(4):
6 All-cause mortality, % Liver-related mortality or liver transplantation, % Viral Eradication is Associated with Reduced Mortality SVR=CURE HCV PCR negative weeks after stopping therapy 530 Europeans followed median 8.4 years after HCV treatment 192 (36%) achieved SVR P<0.001 All-cause mortality Liver-related mortality or liver transplantation P< Without SVR Time, y With SVR No. at risk Without SVR With SVR Without SVR Time, y With SVR No. at risk Without SVR With SVR Van der Meer, et al. JAMA 2012:308:
7 Which of the following does not improve with SVR? A. Lower rate of liver cancer B. Lower rate of liver transplant C. Lower rate of overall death D. Lower rate of AIDS death E. All of these are true 20% 20% 20% 20% 20% A. B. C. D. E. 8
8 SVR Improves Outcomes 711 HIV-HCV; 31% with SVR Berenguer et al. Hepatology 2009;50:
9 Antiretroviral-treated co-infected patients have WHAT rate of hepatic decompensation compared to those mono-infected with HCV? A. The same B. Lower C. Higher D. We don t know 25% 25% 25% 25% A. B. C. D. 8
10 Co-infected Patients have Higher Rates of Hepatic Decompensation Despite ART Lo Re et al. Ann Intern Med. 2014:160:
11 Co-infected Patients have Higher Rates of Hepatic Decompensation Despite ART Lo Re et al. Ann Intern Med. 2014:160:
12 Meet Maya Maya is HIV-HCV infected and very interested in treatment. She has never received HCV therapy HCV G1A, Excellent hepatic function, Plts 220K
13 What therapy would you suggest? A. Begin PEG- IFN/RBV/telaprevir (TVR) B. Begin PEG- IFN/RBV/boceprevir (BOC) C. Begin therapy for PEG- IFN/RBV/ simeprevir (SMV) D. Begin therapy for PEG- IFN/RBV/sofosbuvir (SOF) E. Defer therapy for all-oral option 0% 0% 0% 0% 0% A. B. C. D. E.
14 Treat Now or Wait? Three Major Issues Urgency of Treatment Degree of injury Risk of progression Extrahepatic manifestations Toxicity of therapy Probability of Cure
15 The historical perspective: Treatment of Coinfection vs. Monoinfection 48 weeks PEG+RBV Hadziyannis et al. Ann Int Med 2004; Fried et al. NEJM 2002; Torriani et al NEJM 2004; Nunez et al (PRESCO) AIDS Res Human Retro 2007
16 Milestones in Therapy of HCV: Overall SVR Rates (Mono-infection) Average SVR Rates from Clinical Trials %* 68%* % 54-56% 34% 42% 39% 42-46% 6% 16% Peg-IFN/ RBV 12m DAA+DAA DAA+PR Adapted from Strader DB, et al. Hepatology. 2004;39(4): Hezode C, et al. N Engl J Med. 2009; 360(18): Kwo P, et al. Presented at: EASL; April 23, 2009; Copenhagen, Denmark. Abstract 4. Kwo PY, et al. Lancet. 2010;376(9742): Jacobson IM, et al. N Engl J Med. 2011;364: ; Poordad F, et al. N Engl J Med. 2011;364(13): Telaprevir prescribing information at Accessed September 12, 2012.
17 Currently Available Agents Protease Inhibitor (PI) Boceprevir (TID) Telaprevir (TID) Simeprevir (QD) Additional Regimen Components PEGIFN alfa + weight-based RBV Considerations Genotype Naïve Previous treatment failure Compensated cirrhosis Response guided therapy Polymerase Inhibitor Additional Regimen Components Sofosbuvir (QD) PEGIFN alfa + weight-based RBV Considerations SOF+RBV for genotype 2/3 SOF+PEG/RBV G1 PEGIFN alfa = peginterferon alfa RBV = ribavirin
18 Simeprevir (SMV) + PEG-RBV SMV 150mg QD + PEG-IFN + RBV PEG-IFN + RBV f/u 24 wk Continue therapy only if HCV RNA <25 IU/mL at Week Weeks 48 Fried MW, et al. Hepatology Aug 2:0. doi: /hep
19 Proportion of patients (%) Proportion of patients achieving SVR12 (%) SVR Rates High in Mono-infected Treatment-naïve Sustained Virological Response (SVR12) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% P<0.001* 210/264 65/130 SMV 150 mg QD + PR 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% SVR12 85% met criteria to continue treatment 91% SMV + PR *Controlling for stratification factors PR, peginterferon + ribivarin; SVR12, sustained virological response (HCV RNA undetectable) 12 weeks after planned treatment Adapted from Jacobson IM, et al. Presented at Digestive Disease Week 2013; May 18-21; Orlando, FL. Sa2072.
20 Overview of PI Adverse Events Telaprevir: Adverse Event, % Telaprevir Containing Arms (n = 1797) PEG-IFN/RBV Arm (n = 493) Rash Pruritus Anemia* Anorectal AEs** 29 7 **Hemorrhoids, anorectal discomfort, anal pruritus, and rectal burning Boceprevir: Adverse Event, % Boceprevir Containing Arms (n = 734) PEG-IFN/RBV Arm (n = 363) Anemia* Dysgeusia Simeprevir: Adverse Event, % Simeprevir Containing Arms (n = 781) PEG-IFN/RBV Arm (n = 397) Rash (+photosensitivity) Pruritus Nausea Myalgia
21 Sofosbuvir G1 PATIENTS SOF 400 mg QD + PEG-IFN + RBV f/u 24 wk Weeks 48 G2/3: ALL ORAL THERAPY SOF 400 mg QD + RBV G3 G2 NR Weeks 48 Lawitz EM, et al. N Engl J Med. 2013;368:
22 SVR Rates in Treatment-Naive Patients Treated with Sofosbuvir+PEG/RBV / / / /327 On treatment Post-treatment Relapse accounted for all virologic failures Lawitz EM, et al. Presented at EASL: The International Liver Congress 2013; April 24-28, 2013; Amsterdam, The Netherlands. Abstract 1411.
23 SVR 12 (%) Sofosbuvir + RBV is an All Oral Therapy in Genotype 2 and P <0.001* Total G2 G3 Cirrhosis *Study met primary endpoint of noninferiority of SOF + RBV to PEG-IFN + RBV. FISSION: SOF + RBV in Treatment-naïve, Genotype 2 or 3 Patients Adapted from Lawitz EM, et al. N Engl J Med. 2013;368(20): PEG- IFN/RBV SOF/RBV
24 Effect of Treatment Duration with Sofosbuvir Plus RBV in HCV Genotype 3 Infected Patients FDA Analysis of FISSION, POSITRON, FUSION, VALENCE wks 24 wks 12 wks 16 wk 24 wk Treatment naïve SVR Relapse Treatment Experienced Mishra P. on behalf of the FDA Sofosbuvir Review Team. October 25, 2013
25 Off-label Treatment Options: COSMOS Study: Simeprevir + Sofosbuvir + RBV in HCV Monoinfection Phase 2a HCV genotype 1 Prior null response HCV RNA >10,000 IU/mL F0-F2 fibrosis Simeprevir + Sofosbuvir + RBV Simeprevir + Sofosbuvir Follow-Up Follow-Up Advanced fibrosis, experienced and Naïve to direct acting antivirals Excluded: HBV or HIV infection Simeprevir + Sofosbuvir + RBV Simeprevir + Sofosbuvir Follow-Up Follow-Up Simeprevir 150 mg qd, sofosbuvir 400 mg qd. Weight-based ribavirin dosing (1000 or 1200 mg bid). Week SVR4 Interim Analysis Lawitz E, et al. 20 th CROI. Atlanta, Abstract 155LB.
26 What Off-label Treatment Options may Exist? COSMOS: Sofosbuvir + Simeprevir ± RBV in GT1 Week 12 Treatment Duration Phase 2a Study: SOF 400 mg QD + SMV 150 mg QD ± RBV x 12 wks Prior null responder patients (F0-F2)* Prior null responder and treatment-naïve patients (F3 or F4) % 26/27 13/14 26/27 14/14 *Similar rates in G1a and 1b SVR 8wks (%) SVR 4wks (%) Lawitz et al. Presented at CROI 2013, Abstract 155LB. Medivir announces interim results from Cohort 2 of the COSMOS study evaluating Simeprevir and Sofosbuvir in HCV patients with METAVIR scores F3-F4. Accessed September 3, 2013.
27 The efficacy of HCV therapy is the same in HIV/HCV as in HCV mono-infection. A. True B. False 0% 0% A. B.
28 TVR+PEG+RBV Naïve HCV G1 with HIV
29 TVR+PEG+RBV SVR 12
30 BOC+PEG+RBV Naïve HCV G1 with HIV Sulkowski M et al. Abstract #47 CROI 2012
31 BOC+PEG+RBV Naïve G1 with HIV Virologic Response Over Time Sulkowski M et al. Abstract #47 CROI 2012
32 ANRS HC26 TelapreVIH Study: Telaprevir- Based HCV Therapy in HCV/HIV Coinfection Phase 2 (n=69) HIV positive HCV genotype 1 Previously failed PR On stable ART CD4 >200 cells/mm 3 HIV RNA <50 copies/ml EPO, G-CSF, TPO-R agonists allowed Excluded: Decompensated cirrhosis HBV or HIV-2 infection Previous null response with cirrhosis PR Lead In Telaprevir + PR Follow-Up Week RVR 8 EVR 16 (HCV RNA <15 IU/mL) Complete RVR 8 Telaprevir + PR Partial RVR 8 Telaprevir + PR SVR 24 Follow-Up SVR 24 PR: peginterferon + ribavirin. Telaprevir 750 mg q8h (1125 mg q8h with efavirenz). Weight-based ribavirin dosing ( mg bid). Telaprevir stopping rules: HCV RNA >1000 IU/mL at week 8 or 12; virologic breakthrough at anytime. ART: ATV/r + FTC/TDF (49%); EFV/FTC/TDF (19%); RAL + FTC/TDF (17%). Baseline characteristics: mean age (50 years); male gender (80%); former IDU (55%); CDC stage C (19%); mean CD4 (630 cells/ml); HIV RNA <50 copies/ml (99%); HCV genotype 1a (70%). Cotte L, et al. 20 th CROI. Atlanta, Abstract 36.
33 Patients (%) ANRS HC26 TelapreVIH Study SVR24 by Baseline Characteristics % 81% 75% 71% 75% 90% 85% 81% 78% 74% 83% 100% 71% Overall (n=69) ATV/r EFV RAL 1A 1B TT F1/2 F3/4 Relapse Break through ART (n=34/13/12/10) HCV Subtype IL28B Genotype Fibrosis Stage Partial Null Previous Response (n=27/6/15/21) Cotte L, et al. 21 th CROI Abstract 668.
34 ANRS HC27 BocepreVIH Study: Boceprevir- Based HCV Therapy in HCV/HIV Coinfection Phase 2 (n=64) HIV positive HCV genotype 1 Previously failed PR On stable ART CD4 >200 cells/mm 3 HIV RNA <50 copies/ml EPO, G-CSF, TPO-R agonists allowed Excluded: Decompensated cirrhosis Child B-C cirrhosis HBV or HIV-2 infection Previous null response with cirrhosis PR Lead In Boceprevir + PR Complete RVR 8 Follow-Up Week RVR 8 EVR 16 (HCV RNA <15 IU/mL) PR Partial RVR 8 SVR 24 Follow-Up SVR 24 PR: peginterferon + ribavirin. Boceprevir 800 mg tid. Weight-based ribavirin dosing ( mg bid). Boceprevir stopping rules: HCV RNA >1000 IU/mL at week 8 or 12; virologic breakthrough at anytime. ART: ATV/r + 2 NRTIs (50%); RAL + 2 NRTIs (42%). Baseline characteristics: mean age (52 years); male gender (75%); former IDU (73%); CDC stage C (22%); mean CD4 (728 cells/ml); HIV RNA <50 copies/ml (95%); HCV genotype 1a (78%). Poizot-Martin I, et al. 20 th CROI. Atlanta, Abstract 37.
35 Patients (%) ANRS HC27 BocepreVIH Study: SVR 12 Results % % 70% 56% 54% 60% 54% 61% 40 41% 40% 43% 24% 20 0 Overall (n=64) ATV/r RAL Others F0/1 F2 F3 TT CC Relapse Partial Null ART (n=32/27/5) Fibrosis Stage (n=21/18/14/11) IL28B Genotype Previous Response (n=20/5/18/21) Poizot-Martin I, et al. 21 th CROI, 2014 Abstract 659LB.
36 Telaprevir and Boceprevir Safety Few discontinuations due to toxicity Proactive anemia management decreased impact of anemia No unexpected adverse events No HIV breakthrough TVR/BOC strong inhibitor of CYP3A4 ART limited Poizot-Martin I, et al. 20 th CROI. Atlanta, Abstract 37. Sulkowski et al. Ann Intern Med 2013;159:86-96
37 Second Wave HCV Therapy Telaprevir and Boceprevir are no longer 1 st line therapy 1. Simple rules 2. Shorter duration of therapy 3. More effective 4. Less drug interactions 5. Less side effects
38 Therapeutic Targets for Direct Acting Antiviral Drug Development Poordad, J Viral Hep, 2012;19: Structural Proteins Hepatitis C Virus Polyprotein Core E1 E2 P7 NS2 NS3 4A NS4B NS5A NS5B Non-Structural Proteins Protease Inhibitors NS5A Inhibitors NS5B Nucleoside Inhibitors NS5B Non-Nucleoside Inhibitors High Potency Multi-genotypic coverage Intermediate to high barrier to resistance High Potency Multi-genotypic coverage Low to intermediate barrier to resistance Intermediate Potency Pan-genotypic coverage High barrier to resistance Intermediate Potency Limited genotypic coverage Low barrier to resistance
39 Second-wave protease inhibitors in HIV/HCV Coinfection
40 Phase III Faldaprevir + PEG/RBV treatment-naïve and relapser patients HCV GT- 1 and HIV infection Dieterich D et al.. STARTVerso 4. 21st Conference on Retroviruses and Opportunistic Infections, 2014; abstract 23
41 SVR in HIV/HCV co-infected patients: Phase III Faldaprevir + PEG/RBV treatment-naïve and relapsers Dieterich D et al.. STARTVerso 4. 21st Conference on Retroviruses and Opportunistic Infections, 2014; abstract 23
42 Study C212: Simeprevir + PR HIV/HCV Coinfection Phase 3 (n=106) On ART (88%) Primary endpoint: SVR12 HCV Treatment-Naïve Relapse Response Guided Therapy Simeprevir + PR Simeprevir + PR PR PR Follow-Up Follow-Up HCV Partial Response HCV Null Response Cirrhotic (F4) Simeprevir + PR Follow-Up Week PR PR: peginterferon + ribavirin. Simeprevir 150 mg qd. ART: NRTI (3TC, ABC, FTC, TDF): 99%. Raltegravir: 87%. Rilpivirine: 15%. Maraviroc: 3%. Enfuvirtide: 3%. Dieterich D, et al. 21 st CROI Abstract 24.
43 Patients (%) Study C212: SVR12 Simeprevir + PR in HIV/HCV Coinfection SVR12 74% 79% 87% 70% 89% 60 57% Overall Naïve Relapse Partial Null RGT-Eligible (n=54/61) PR: peginterferon + ribavirin. Dieterich D, et al. 21 st CROI Abstract 24.
44 Study C212: HCV Relapse and Safety HCV relapse Treatment-naïve and prior relapse: 16% All genotype 1a Prior null responders: 64% No HIV virologic failures Average CD4 cell decline: 670 to >380 cells/mm 3 Simeprevir + PR was well tolerated, with similar safety profile in HCV-monoinfected patients Fatigue (41%), nausea (26%), headache (27%) Neutropenia (27%), anemia (21%), pruritus (20%), rash (17%), photosensitivity (2%) Increased bilirubin (5%) Dieterich D, et al. 20 th CROI. Atlanta, Abstract 154LB.
45 Interferon-Free Treatment HCV Monoinfection Several 8-24 week Interferon Free regimens have demonstrated high efficacy in HCV mono-infected patients
46 SAPPHIRE-I: INF-FREE, 12-WEEK ABT-450/r/ABT-267, ABT-333, + RIBAVIRIN TREATMENT-NAÏVE G1 (N=631) Double-Blind Treatment Period 3D + RBV (n=473) Open-Label Treatment Period 48-Week Follow-Up Placebo (n=158) 3D + RBV 48-Week Follow-Up Week 0 Week 12 Week 24 Week 60 Week 72 Primary Analysis: SVR 12 3D: co-formulated ABT-450/r/ombitasvir, 150 mg/100 mg/25 mg QD; dasabuvir, 250 mg BID RBV: mg daily according to body weight (<75 kg and >75kg, respectively) SAPPHIRE-I Phase 3 Study of ABT-450/r/Ombitasvir + Dasabuvir + RBV in Treatment-Naïve Adults With HCV GT 1 International Liver Congress April
47 SVR12, % Patients SAPPHIRE-I Results: ITT SVR12 Rates % 95.3% 98.0% Superiority threshold The ITT SVR12 rate of 98.0% (95% CI, ) in GT1b-infected patients is superior to a calculated historical SVR12 control rate of 80% (95% CI, ) / / /151 All Patients GT1a GT1b SAPPHIRE-I Phase 3 Study of ABT-450/r/Ombitasvir + Dasabuvir + RBV in Treatment-Naïve Adults With HCV GT 1 International Liver Congress April
48 SAPPHIRE-I Phase 3 Study of ABT-450/r/Ombitasvir + Dasabuvir + RBV in Treatment-Naïve Adults With HCV GT 1 International Liver Congress April
49 SAPPHIRE-I: Adverse Events Occurring in >10% of Patients in Either Group Event, n (%) 3D + RBV (N=473) Placebo (N=158) P Value Any AE 414 (87.5) 116 (73.4) <0.05 Fatigue 164 (34.7) 45 (28.5) NS Headache 156 (33.0) 42 (26.6) NS Nausea 112 (23.7) 21 (13.3) <0.05 Pruritus 80 (16.9) 6 (3.8) <0.05 Insomnia 66 (14.0) 12 (7.6) <0.05 Diarrhea 65 (13.7) 11 (7.0) <0.05 Asthenia 57 (12.1) 6 (3.8) <0.05 Rash 51 (10.8) 9 (5.7) NS AEs were generally mild. SAPPHIRE-I Phase 3 Study of ABT-450/r/Ombitasvir + Dasabuvir + RBV in Treatment-Naïve Adults With HCV GT 1 International Liver Congress April
50 SVR12, % Patients SAPPHIRE-II INF-Free 12 week Regimen ABT-450r/ABT-267, ABT333, RBV in Treatment-Experienced: ITT SVR12 Rates % 96.0% 96.7% Superiority threshold (77%) The ITT SVR12 rate of 96.7% (95% CI, ) in GT1b-infected patients is superior to a calculated historical SVR12 control rate of 71% (95% CI, 64-77) / / /123 All Patients GT1a GT1b SAPPHIRE-I Phase 3 Study of ABT-450/r/Ombitasvir + Dasabuvir + RBV in Treatment-Naïve Adults With HCV GT 1 International Liver Congress April
51 SVR12, % Patients SAPPHIRE-II Results: ITT SVR12 Rates >95% in All Prior Peginterferon/Ribavirin Response Groups % 100% 95.2% /86 65/65 139/146 Prior Relapse Prior Partial Response Prior Null Response SAPPHIRE-I Phase 3 Study of ABT-450/r/Ombitasvir + Dasabuvir + RBV in Treatment-Naïve Adults With HCV GT 1 International Liver Congress April
52 SVR12, % Patients TURQUOISE-II: Cirrhosis; Naïve or Treatment Experienced G1 ITT SVR12 Rates of 92% to 96% P= Superiority threshold: 54% Non-inferiority threshold: 43% / Weeks 3D + RBV 165/ Weeks 3D + RBV SAPPHIRE-I Phase 3 Study of ABT-450/r/Ombitasvir + Dasabuvir + RBV in Treatment-Naïve Adults With HCV GT 1 International Liver Congress April
53 Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection (ION) Mangia EASL 2014; Afdhal N et al. NEJM. 2014;on-line 4/12/14
54 Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study Afdhal et al. EASL 2014; Afdhal N et al. NEJM. 2014;on-line 4/12/14
55 NIH SYNERGY: HCV Treatment Naïve G1 NPI-NS5A+/- NNPI or PI NPI+NS5B NPI+NS5B NNPI NPI+NS5B PI Kohli A, et al. CROI 2014 Abstract 27LB
56 Kohli A, et al. CROI 2014 Abstract 27LB NIH SYNERGY TRIAL
57 Interferon-Free Treatment HCV-HIV Co-infection Growing data that HIV Co-Infection is no longer a special population
58 PHOTON-1: Sofosbuvir +RBV HIV-Co-Infected Treatment Naïve with G1,2,3 Experienced G2/3 Sofosbuvir HCV NS5B nucleotide inhibitor 4-14% with cirrhosis 93-98% on ART Naggie S, et al CROI 2014 Abstract 26
59 PHOTON 1: SOF+RBV HIV/HCV SVR 12 and 24 Genotype 1 Genotype 2 Genotype 3 Naggie S, et al CROI 2014 Abstract 26
60 C-WORTHY: HIV/HCV G1 Naïve, Non-Cirrhotic MK-5172 (NS3/4A)+MK-8742 (NS5A)+/- RBV ART: raltegravir+two NRTIs for at least 8 weeks prior to enrollment Sulkowski M, et al. 21 st CROI. Abstract 654LB
61 C-WORTHY MK-5172 (NS3/4A)+MK-8742 (NS5A)+/- RBV On Treatment Response Rate Sulkowski M, et al. 21 st CROI. Abstract 654LB SVR4: 97% with RBV; 90% without RBV
62 % of patients with HCV RNA < LLOQ ERADICATE Study (NIAID, LDV/SOF) LDV/SOF STR for Treatment of HCV GT 1 Co-infected with HIV (Interim Analysis) Study Weeks N = 50 GT 1, TN, stable HIV disease ARV Untreated: LDV/SOF ARV Treated*: LDV/SOF SVR 4 SVR 12 Interim results ARV Untreated ARV Treated / 13 37/ 37 13/ 13 37/ 37 13/ 13 30/ 30 Week 4 Week 8 EOT SVR4 SVR8 SVR12 12/ 12 22/ 22 10/ 10 10/ 10 LDV/SOF STR was well tolerated with no discontinuations Osinusi A, EASL, 2014, O14 62
63 Drug Interactions Must Be Discussed Currently approved protease inhibitors have many potential drug interactions Coadministered may inhibit or induce various metabolic pathways (eg, CYP3A, P-gp) Solutions may be found for virtually all potential drug-drug interactions
64 Concentration Drug-drug Interactions (DDIs) with Current PIs Drug interactions may affect blood levels of either PI or co-administered drug Drug + PI PI blocks the function of the CYP enzyme P Time PI (acting as inhibitor) may AUC of drug Drug acting as inducer may AUC of PI AUC=area under the curve Caution is needed with ALL co-administered medications Review package inserts for interaction lists Reconcile patient medication list Patient needs to communicate new meds started by other health care providers Other resource:
65 Summary SVR decreases liver and all-cause mortality HIV/HCV co-infection increases risk for hepatic deompensation SVR rates for HIV/HCV are comparable to mono-infection SMV and SOF will offer more treatment options for many patients Highly effective all-oral therapies are anticipated in the new future
66 Thank you!?
67 Activity Code FA376
Associate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationHIV Infection with HCV Future Directions
HIV Infection with HCV Future Directions Dr Ranjababu (Babu) Kulasegaram Consultant Physician in HIV/GU Medicine Guy s and St Thomas NHS Foundation Trust London, UK Presenter disclosure information Dr
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationHIV-HCV Co-Infection. George Mason University Falls Church, Virginia. Overview. Prevalence of HCV co-infection Incidence and Recent Trends
HIV-HCV Co-Infection Zobair Younossi MD, MPH, FACG, AGAF, FAASLD Chairman, Department of Medicine, Inova Fairfax Hospital Vice President for Research, Inova Health System Professor of Medicine, VCU-Inova
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationSlide Presentation. Management of HCV Coinfection Susanna Naggie, MD, MHS
Slide Presentation Management of HCV Coinfection Assistant Professor of Medicine Duke University School of Medicine & Durham VA Medical Center Director of Infectious Diseases Duke Clinical Research Institute
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationHCV Treatment: Why to Wait
HCV Treatment: Why to Wait Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationUpdates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today
Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today The treatment paradigm for hepatitis C virus (HCV) is changing very rapidly. In the short time since
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationCan a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients?
Can a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients? Ira M. Jacobson, MD Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationWorkshop I Planning Committee
Workshop I Planning Committee Nancy Reau, MD Associate Professor of Medicine University of Chicago School of Medicine Chicago, IL Stuart C. Gordon, MD Professor of Medicine Wayne State University School
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationPreliminary Results of an Evaluation of Ledipasvir/Sofosbuvir in Patients with Chronic HCV or HCV/HIV Co-Infection
Preliminary Results of an Evaluation of Ledipasvir/Sofosbuvir in Patients with Chronic HCV or HCV/HIV Co-Infection Konstantin Zhdanov 1, Viacheslav Morozov 2, Elena A Orlova-Morozova 3, Riina Salupere
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationUPDATES IN HEPATITIS C
UPDATES IN HEPATITIS C S A R A H N A I D O O, P H A R M, B C P S AP RI L 13, 2014 OBJECTIVES Be able to discuss changes in hepatitis c treatment Be able to provide recommendations to providers regarding
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More information